Susceptibility of antigen-specific CD4 T cells to HIV: implications for HIV vacci
抗原特异性 CD4 T 细胞对 HIV 的敏感性:对 HIV 疫苗的影响
基本信息
- 批准号:9070878
- 负责人:
- 金额:$ 13.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-02-05 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:ALVACAcquired Immunodeficiency SyndromeAddressAffectAntigensAntiviral AgentsAreaBiological AssayCD4 Positive T LymphocytesCandidaCandida albicansCell LineCellsClinicalClinical ResearchCytomegalovirusDataDevelopmentDifferentiation AntigensExposure toGene ExpressionGenesHIVHIV InfectionsHIV therapyHIV vaccineHIV-1HIV/SIV vaccineHomingHumanImmunityImmunizationInfectionKnowledgeLabelLaboratoriesLeadMeasuresMemoryMicroarray AnalysisMolecularOpportunistic InfectionsOutcomePathogenesisPathway interactionsPatientsPeripheralPeripheral Blood Mononuclear CellPhenotypePopulationPredispositionPrincipal InvestigatorProliferatingProteinsPublic HealthRNARelative (related person)ReportingResistanceRiskRoleSamplingSiteSmall Interfering RNASorting - Cell MovementSpecificitySurrogate MarkersSystemT cell responseT-LymphocyteTestingTetanus ToxoidTimeTranscriptVaccine DesignVaccinesViralbasecytokinedifferential expressiongenome-widein vitro Assayinsightmemory CD4 T lymphocytenovelpandemic diseasepathogenpermissivenesspre-clinicalprogramspublic health relevanceresearch studysensorvaccine efficacyvaccine trialvaccine-induced immunityvectorvector-inducedviral RNA
项目摘要
DESCRIPTION: A central question to better understanding the pathogenesis of HIV infection is how memory CD4 T cells are infected and progressively depleted by HIV. Little is currently known about the impact of HIV infection on CD4 T cells of different pathogen or antigen specificities. Exploring this area is important for better understanding of the timing of different
opportunistic infections in AIDS patients. In addition, identification of a functional population o vaccine-specific CD4 T cells that is "resistant" to HIV is critical for HIV vaccine design.
We have established a novel system for studying the susceptibility of antigen-specific CD4 T cells to HIV, and have found that different antigen-specific CD4 T cells manifest marked differences in susceptibility to HIV infection. Our preliminary data show that compared to CD4 T cells specific to tetanus toxoid (TT) and Candida albicans (Candida), which are permissive to HIV, cytomegalovirus (CMV)-specific CD4 T cells are highly resistant to both R5 and X4 HIV with post-entry HIV restriction. Our microarray analysis identified a novel viral RNA sensor, IFIT1 that is highly upregulated in CMV-specific CD4 T cells. Of importance, in our ongoing experiments, we show that over-expression of IFIT1 significantly inhibits HIV infection in A3R5 CD4 T cell line. Based on data already generated, we hypothesize that IFIT1 can inhibit HIV infection in human primary CD4 T cells and differential expression of IFIT1 regulates the permissiveness of antigen-specific CD4 T cells to HIV.
We further propose to extend the novel system and observations to clinical HIV vaccine studies. Preferential infection of vaccine-generated CD4 T cells by HIV reduces the efficiency of vaccine-induced immunity. Our hypothesis is that a protective HIV vaccine would induce a type of vaccine-specific CD4 T cells that are "not readily susceptible" to HIV, and that different candidate HIV vaccines (e.g. different vectors) induce distinct phenotypes of vaccine-specific CD4 T cells that may significantly impact their sensitivities to HIV. We will test peripheral blood
mononuclear cell samples from three completed HIV vaccine trials: RV144 (ALVAC), RV158 (MVA) and IPVC001 (Ad26). Our hypotheses will be addressed in 2 Specific Aims: 1) To determine the role of IFIT1 in regulating the susceptibility of human antigen-specific CD4 T cells to HIV and to further explore the mechanisms for inhibition of HIV by IFIT1; 2) To investigate the susceptibilities of different HIV vaccine-induced, antigen-specific CD4 T cells to HIV infection and the associated phenotypes in HIV vaccine trials.
The proposed studies are exploratory, but expected to provide new insights to: 1) understand the mechanisms for the persistence of CMV-specific T cell immunity in AIDS patients; 2) identify a novel anti-HIV molecule with previously unidentified inhibitory mechanisms/pathways that could lead to the development of novel HIV therapies; 3) better understand the quality of vaccine-generated CD4 T cell immunity and to provide proof of concept knowledge on whether and how to induce functional, "HIV-resistant" CD4 T cells by an HIV vaccine.
描述:为了更好地了解HIV感染的发病机制,一个中心问题是记忆CD4T细胞是如何被HIV感染并逐渐耗尽的。目前对HIV感染对不同病原体或抗原特异性的CD4T细胞的影响知之甚少。探索这一领域对于更好地理解不同的
艾滋病患者的机会性感染。此外,确定对HIV具有“抵抗力”的疫苗特异性CD4T细胞的功能群体对HIV疫苗设计至关重要。
我们建立了一种新的系统来研究抗原特异性的CD4T细胞对HIV的易感性,并发现不同的抗原特异性的CD4T细胞对HIV感染的敏感性有明显的差异。我们的初步数据显示,与破伤风类毒素(TT)和白色念珠菌(Candida)特异性的CD4T细胞相比,巨细胞病毒(CMV)特异性的CD4T细胞对进入后HIV限制的R5和X4HIV都具有高度的抵抗力。我们的微阵列分析发现了一种新的病毒RNA传感器IFIT1,它在CMV特异性的CD4T细胞中高度上调。重要的是,在我们正在进行的实验中,我们表明Ifit1的过表达显著抑制了A3R5 CD4T细胞系中的HIV感染。基于已经产生的数据,我们假设IFIT 1可以抑制人类原代CD4T细胞中的HIV感染,并且IFIT 1的差异表达调节抗原特异性CD4T细胞对HIV的许可。
我们进一步建议将新的系统和观察扩展到临床艾滋病毒疫苗研究。HIV优先感染疫苗产生的CD4T细胞会降低疫苗诱导免疫的效率。我们的假设是,保护性HIV疫苗将诱导一种疫苗特异性的CD4T细胞,这些细胞对HIV不容易敏感,而不同的候选HIV疫苗(例如,不同的载体)会诱导不同的疫苗特异性CD4T细胞的表型,这可能会显著影响它们对HIV的敏感性。我们会检测外周血
来自三个已完成的艾滋病毒疫苗试验的单个核细胞样本:RV144(ALVAC)、RV158(MVA)和IPVC001(AD26)。我们的假设将针对两个特定目标:1)确定IFIT 1在调节人类抗原特异性CD4T细胞对HIV的易感性中的作用,并进一步探索IFIT 1抑制HIV的机制;2)研究不同HIV疫苗诱导的抗原特异性CD4T细胞对HIV感染的易感性及其在HIV疫苗试验中的相关表型。
拟议中的研究是探索性的,但预计将为以下方面提供新的见解:1)了解艾滋病患者CMV特异性T细胞免疫持续的机制;2)确定一种新的抗HIV分子,其抑制机制/途径以前未知,可能导致新的HIV疗法的开发;3)更好地了解疫苗产生的CD4T细胞免疫的质量,并提供关于是否以及如何通过HIV疫苗诱导功能性的、“抗HIV的”CD4T细胞的概念证明知识。
项目成果
期刊论文数量(7)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Priming and Activation of Inflammasome by Canarypox Virus Vector ALVAC via the cGAS/IFI16-STING-Type I IFN Pathway and AIM2 Sensor.
- DOI:10.4049/jimmunol.1700698
- 发表时间:2017-11-01
- 期刊:
- 影响因子:0
- 作者:Liu F;Niu Q;Fan X;Liu C;Zhang J;Wei Z;Hou W;Kanneganti TD;Robb ML;Kim JH;Michael NL;Sun J;Soong L;Hu H
- 通讯作者:Hu H
HIV Susceptibility of human antigen-specific CD4 T cells in AIDS pathogenesis and vaccine response.
- DOI:10.1586/14760584.2016.1147354
- 发表时间:2016-06
- 期刊:
- 影响因子:6.2
- 作者:Hu H;Liu F;Kim J;Ratto-Kim S
- 通讯作者:Ratto-Kim S
Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy.
非小细胞肺癌脑转移患者的突变状态和切除后生存:生物标志物驱动治疗的影响。
- DOI:10.3171/2020.10.jns201787
- 发表时间:2022
- 期刊:
- 影响因子:4.1
- 作者:Shah,PavanP;Franke,JenniferL;Medikonda,Ravi;Jackson,ChristopherM;Srivastava,Siddhartha;Choi,John;Forde,PatrickM;Brahmer,JulieR;Ettinger,DavidS;Feliciano,JosephineL;Levy,BenjaminP;Marrone,KristenA;Naidoo,Jarushka;Redmond,
- 通讯作者:Redmond,
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Haitao Hu其他文献
Haitao Hu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Haitao Hu', 18)}}的其他基金
Modulation of BRD4 to epigenetically suppress HIV
调节 BRD4 以表观遗传抑制 HIV
- 批准号:
10624845 - 财政年份:2021
- 资助金额:
$ 13.95万 - 项目类别:
Modulation of BRD4 to epigenetically suppress HIV
调节 BRD4 以表观遗传抑制 HIV
- 批准号:
10326722 - 财政年份:2021
- 资助金额:
$ 13.95万 - 项目类别:
Modulation of BRD4 to epigenetically suppress HIV
调节 BRD4 以表观遗传抑制 HIV
- 批准号:
10434159 - 财政年份:2021
- 资助金额:
$ 13.95万 - 项目类别:
In vitro and in vivo analysis of susceptibility of Ad26 vector-induced CD4 T cells to HIV/SIV
Ad26载体诱导的CD4 T细胞对HIV/SIV敏感性的体外和体内分析
- 批准号:
10010193 - 财政年份:2020
- 资助金额:
$ 13.95万 - 项目类别:
In vitro and in vivo analysis of susceptibility of Ad26 vector-induced CD4 T cells to HIV/SIV
Ad26载体诱导的CD4 T细胞对HIV/SIV敏感性的体外和体内分析
- 批准号:
10115603 - 财政年份:2020
- 资助金额:
$ 13.95万 - 项目类别:
Susceptibility of antigen-specific CD4 T cells to HIV: implications for HIV vacci
抗原特异性 CD4 T 细胞对 HIV 的敏感性:对 HIV 疫苗的影响
- 批准号:
8732199 - 财政年份:2014
- 资助金额:
$ 13.95万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 13.95万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 13.95万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 13.95万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 13.95万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 13.95万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 13.95万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 13.95万 - 项目类别: